Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title: Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month – Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial. Reference: Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this<a href="https://solaci.org/en/2015/01/15/never-ending-controversy-over-the-duration-of-post-des-dual-antiplatelet-therapy/" title="Read more" >...</a>

Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent

Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66.   Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a<a href="https://solaci.org/en/2015/01/13/risks-and-benefits-of-dual-antiplatelet-beyond-the-year-of-a-drug-eluting-stent/" title="Read more" >...</a>

Patent Foramen Ovale: when to indicate closure

References: Matthew Nayor et al. Contemporary Approach to Paradoxical Embolism. Circulation. 2014;129:1892-1897. Marco Hernandez-Enrıquez et al.  Current Indications for Percutaneous Closure of Patent Foramen Ovale.  Rev Esp Cardiol. 2014;67(8):603–607. The debate on patent foramen ovale behavior in different clinical contexts remains open, no pun intended. Based on numerous observational studies and expert recommendations, when facing the<a href="https://solaci.org/en/2014/10/27/patent-foramen-ovale-when-to-indicate-closure/" title="Read more" >...</a>

Proximal protection devices could be the first choice for most carotid artery stenting procedures

Original title: Evaluation of proximal protection devices during carotid artery stenting as the first choice for embolic protection. Reference: Hornung M et al. EuroIntervention. 2014; Epub ahead of print. This series of the Frankfurt CardioVascular Center included 124 consecutive patients undergoing carotid angioplasty with proximal protection. The first 92 patients received the Gore Flow Reversal System (WL Gore;<a href="https://solaci.org/en/2014/07/31/proximal-protection-devices-could-be-the-first-choice-for-most-carotid-artery-stenting-procedures/" title="Read more" >...</a>

SYNTAX study final monitoring at 5-years

Original title: Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Reference: Eur Heart J. 2014 May 21. pii: ehu213. (Epub ahead of print). The SYNTAX study was one of the largest randomized clinical studies comparing long-term results of angioplasty versus surgery in multivessel disease and /or<a href="https://solaci.org/en/2014/07/04/syntax-study-final-monitoring-at-5-years/" title="Read more" >...</a>

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents. Reference: El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/3-to-6-months-of-dual-antiplatelet-after-des-reduced-bleeding-and-did-not-raise-mortality-or-infarction/" title="Read more" >...</a>

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of the ABSORB and the SPIRIT Trials. Reference: Muramatsu T et al. JACC CardiovascInterv. 2014 May;7(5):482-93. This study included ABSORB, ABSORB Extend and SPIRIT patients. A total of 136 diabetic patients and 415 non diabetic receiving everolimus-eluting bioresorbable scaffolds (Absorb) and<a href="https://solaci.org/en/2014/06/10/1-year-clinical-outcomes-of-everolimus-eluting-bioresorbable-vascular-scaffolds-in-diabetic-patients/" title="Read more" >...</a>

Orbital Atherectomy improves calcified lesions treatment outcomes

Original title: Pivotal Trial to Evaluate the Safety and Efficacy of the Orbital Atherectomy System in Treating de Novo, Severely Calcified Coronary Lesions (ORBIT II) Reference: Jeffrey Chambers, et al. JACC Intervention 2014;7:510-8 Severely calcified coronary lesions, traditionally associated to difficult or impossible stent implantation, asymmetric stent expansion, higher post procedural events rate, more restenosis, more lesion revascularization,<a href="https://solaci.org/en/2014/06/02/orbital-atherectomy-improves-calcified-lesions-treatment-outcomes/" title="Read more" >...</a>

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title: Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. Reference:  EuroIntervention 2014; 9-online publish-ahead-of-print February 2014   The aim of this study was to compare strut coverage at six months follow up after Nobori biolimus eluting stent (N- BES) implantation versus Cypher Select sirolimus eluting stent (SES) implantation.<a href="https://solaci.org/en/2014/05/27/higher-percentage-of-strut-coverage-in-biodegradable-polymer-des-vs-durable-polymer-des-strut-level-oct-analyses/" title="Read more" >...</a>

Severe coronary calcification is a predictor of coronary events in acute coronary syndromes

Original title: Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Pooled Analysis From the HORIZONS and ACUITY Trials. Reference: Philippe Généreux, et al. J Am Coll Cardiol 2014;63:1845-54 Calcification of the arteries has always been a challenge and a generator of problems during coronary angioplasty, but its impact on acute coronary syndromes has not<a href="https://solaci.org/en/2014/05/21/severe-coronary-calcification-is-a-predictor-of-coronary-events-in-acute-coronary-syndromes/" title="Read more" >...</a>

thrombosis